Previous 10 | Next 10 |
Summary Regeneron reported preliminary Eylea U.S. net sales in early January that were below expectations. The net sales miss was not driven by increasing pressure from Vabysmo but by a temporary shutdown of a fund that helps with patient copays. Management said they are already see...
Regeneron ( NASDAQ: REGN ) shares edged higher pre-market Monday after Cowen upgraded the biotech to Outperform from Market Perform citing the long-term potential of the eye disease therapy Eylea the company markets with Bayer AG ( OTCPK:BAYZF ) ( OTCPK:BAYRY ). Regeneron ( ...
A pproximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo Dupixent is now an option for the app...
A committee of the European Medicines Agency (EMA) recommended granting expanded approval to Sanofi ( NASDAQ: SNY ) and Regeneron Pharmaceuticals ( NASDAQ: REGN ) Dupixent to treat severe atopic dermatitis (eczema) in children six months to five years old who a...
If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related ...
Nation’s Most Innovative Teens will Showcase Research with Prizes of Over $1.8 million TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40...
The job of an investor is to buy top-notch companies in essential economic sectors at reasonable valuations and hold them over the long term. Because everyone will need access to healthcare services in their life, healthcare is an especially important sector of the economy. In that spirit...
Shares of Regeneron Pharmaceuticals Inc ( NASDAQ: REGN ) have already gained about 25% since early September but a JPMorgan analyst is convinced the stock will continue to move up in the coming months. Regeneron shares could climb further to $850 Chris Schott recommends that investors...
Regeneron ( NASDAQ: REGN ) shares trended higher pre-market Friday after JPMorgan upgraded the stock to Overweight from Neutral, noting several key catalysts in 2023, including the upcoming launch of high-dose Eylea. Citing the company’s early earnings results, JPMorgan analyst...
The World Health Organization (WHO) said that individuals should wear masks in certain situations irrespective of the local spread of COVID-19 given the current spread of the virus worldwide. Masks are recommended if one has had recent exposure to COVID, when someone has or suspects they have...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...